PULMOTECT, INC.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.pulmotect.com
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- Conditions
- Hematologic MalignanciesHematopoietic Stem Cell Transplant (HSCT)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Pulmotect, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06665100
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Pulmotect, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT04312997
- Locations
- 🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸Premeir Urgent Care of California, San Bernardino, California, United States
🇺🇸Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Pulmotect, Inc.
- Target Recruit Count
- 217
- Registration Number
- NCT04313023
- Locations
- 🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸Premier Urgent Care of California, San Bernardino, California, United States
🇺🇸Clinical Research of South Florida Alliance for Multispecialty Research, Coral Gables, Florida, United States
The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD
- Conditions
- COPD
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Pulmotect, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03794557
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, St Mary Hospital, London, United Kingdom
A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Pulmotect, Inc.
- Registration Number
- NCT03097796
- Locations
- 🇺🇸
University of Texas MD Anderson MD Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- Next